Newsfeeds - Spark Newswire

1 minute read

Guggenheim Reiterates Buy on Larimar Therapeutics, Maintains $12 Price Target

Today, 5:31 PM

Guggenheim analyst Yatin Suneja reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Buy and maintains $12 price target.

LRMR

1 minute read

Larimar Therapeutics Q4 EPS $(0.21) Beats $(0.37) Estimate; Cash & Investments Of $118.4M Provides Projected Cash Runway Into 2H 2024

By Benzinga Newsdesk

Today, 5:31 PM

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.37) by 43.24 percent. This is a 58 percent increase over losses of $(0.50) per share from

LRMR

1 minute read

Citigroup Initiates Coverage On Larimar Therapeutics with Neutral Rating, Announces Price Target of $4

By Benzinga Newsdesk

Today, 5:31 PM

Citigroup analyst Samantha Semenkow initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Neutral rating and announces Price Target of $4.

LRMR

2 minute read

$35 Million Bet On This Penny Stock? Check Out These 3 Stocks Under $4 Insiders Are Buying

By Lisa Levin

Today, 5:31 PM

The Dow Jones dropped by more than 300 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

ADV

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 19, 2022

By Benzinga Insights

Today, 5:31 PM

Upgrades

ADBE

1 minute read

JMP Securities Maintains Market Outperform on Larimar Therapeutics, Raises Price Target to $16

By Benzinga Newsdesk

Today, 5:31 PM

JMP Securities analyst Jonathan Wolleben maintains Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and raises the price target from $10 to $16.

LRMR